Baricitinib for Adults With Active Cardiac Sarcoidosis
Tests baricitinib alongside another medicine in adults with active cardiac sarcoidosis.
Key facts
- Who runs it
- Stanford University
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Registry title
- A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 10 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Baricitinib (LY3009104) 4 mg
- Record updated
- 10 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active cardiac sarcoidosis (inflammation in the heart caused by sarcoidosis). They will take baricitinib with a steroid-sparing medicine for up to 16 weeks.
- Age
- 18 Years to 85 Years
- Sex
- All sexes can join.
- Disease stage
- Active cardiac sarcoidosis. It must be shown by a biopsy or by heart problems with no other cause. A cardiac FDG PET-CT scan within 6 weeks of screening must show active disease.
- Earlier treatment
- People cannot currently take immune-suppressing medicines other than one steroid-sparing medicine (such as methotrexate, leflunomide, azathioprine or mycophenolate mofetil) and/or prednisone (or equivalent) at ≤ 20mg daily. No biologic or JAK inhibitor medicines within 28 days before screening. No B cell-depleting therapy (such as rituximab) in the 6 months before screening.
- Biomarker or test result
- Abnormal FDG uptake on a cardiac PET-CT scan, in a pattern of active cardiac sarcoidosis.
Main reasons for not taking part
- Past blood clots in the veins, or a higher risk of them
- Current smoking
- Severe kidney problems (eGFR < 30 mL/min/1.73 m2) or abnormal liver or blood tests
- Active, serious infection at screening
- Cancer that was active within the last 5 years, with some exceptions
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Diagnosis of cardiac sarcoidosis based on one of the following pathways:; Histological Diagnosis; Myocardial or extracardiac biopsy demonstrating non-caseating granuloma with no alternative cause identified AND; Abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND; Exclusion of other causes for cardiac manifestations; Clinical Diagnosis; One or more of the following is present:; Steroid +/- immunosuppressant responsive cardiomyopathy or heart block; Unexplained reduced LVEF (< 40%) and/or segmental wall motion abnormalities not related to coronary artery disease or another defined cause; Unexplained sustained (spontaneous or induced) VT; Mobitz type II 2nd degree heart block or 3rd degree heart block; CT chest and/or FDG PET-CT showing features consistent with pulmonary sarcoidosis and/or hilar lymphadenopathy AND; Abnormal FDG uptake on cardiac PET-CT conducted within 6 weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND; Exclusion of other causes for cardiac manifestations
- Active cardiac sarcoidosis based on abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis
- No current treatment with immunosuppressive medications other than a steroid-sparing medication (including methotrexate, leflunomide, azathioprine, or mycophenolate mofetil), and/or prednisone (or equivalent) at a dose of ≤ 20mg daily at Baseline
Who cannot take part
- Receipt of a non-biologic DMARD or immunosuppressive agent other than methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, or glucocorticoids within 28 days prior to screening
- Receipt of a bDMARD or tsDMARD, including non-depleting B-cell-directed therapy (eg, belimumab), T cell costimulatory blockade (eg, abatacept), TNF-alpha inhibition (eg, infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), interleukin-6 inhibition (eg, tocilizumab, sarilumab), interleukin-1 inhibition (eg, anakinra), JAK inhibition (eg, tofacitinib, upadacitinib, baricitinib), or other biologic immunomodulatory agent within 28 days prior to screening
- History of venous thromboembolism (VTE) or an increased risk for VTE
- Estimated glomerular filtration rate < 30 mL/min/1.73 m2 by Modification of Diet in Renal Disease Study (MDRD) equation
- Active, clinically significant infection at the time of Screening
- Receipt of any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab) in the 6 months prior to screening; receipt of such a B cell-depleting agent in the period 6-12 months prior to screening is exclusionary unless B cell counts have returned to ≥ LLN
- Blood tests at screening that meet any of the following criteria:; Hemoglobin < 7.5 g/dL; Neutrophils < 1000/mm3; Absolute lymphocyte count < 500/mm3; Platelets < 100 x 109/L
- Subjects with the following abnormal liver function tests:; Aspartate aminotransferase (AST) > 2x ULN; Alanine aminotransferase (ALT) > 2x ULN; Total bilirubin (TBL) > 2x ULN unless AST, ALT, and hemoglobin are within central laboratory normal range and the patient has a known history of Gilbert syndrome
- Active malignancy or history of malignancy that was active within the last 5 years, except as follows:; In situ carcinoma of the cervix following apparently curative therapy > 12 months prior to screening,; Cutaneous basal cell or squamous cell carcinoma following apparently curative therapy, or; Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent > 3 years prior to screening and without known recurrence or current treatment
- Current smoking
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in United States
- Stanford UniversityPalo Alto, United StatesContact: Angie AberiaNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:
Read full original descriptionShow less
- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?
Participants will:
* Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib
The group in the trial
- baricitinib + steroid-sparing drug +/- glucocorticoid taperTreatment being tested
* Participants will be treated with baricitinib 4 mg daily for up to 16 weeks in combination with a background steroid sparing medication * Participants who are on steroids at the time of enrollment will continue the steroid at a dose of prednisone (or equivalent) ≤ 20mg PO daily at Baseline and complete an 8 week taper of their steroid medication per a standardized protocol
Treatment: Baricitinib (LY3009104) 4 mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis
- Plain-language title
- Baricitinib for Adults With Active Cardiac SarcoidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06868381, who can take part
- Record updated
- 10 February 2026